## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims**

1. (Original): A compound according to formula I

$$P_1$$
  $P_2$   $P_3$   $P_4$   $P_4$   $P_4$   $P_5$   $P_6$   $P_8$   $P_8$   $P_8$ 

wherein

- P represents -N < or -C=,
- X represents independently of each other -CH<sub>2</sub>-, CR<sub>1</sub> (Sp<sub>2</sub>- hybridised), O, -NH-, =N-, -CO- or -CS-, wherein R<sub>1</sub> represents H or NR<sub>2</sub>, wherein R<sub>2</sub> represents H or lower alkyl, which optionally is linked to Z such that a bicyclic structure is formed;
- n represents 1 or 2,
- R<sub>a</sub> represents H, lower alkyl, -OR<sub>3</sub>, -O (CO) R<sub>3</sub>, -O (CO) OR<sub>3</sub>, -O (CO) NR<sub>3</sub>R<sub>4</sub>, -N<sub>3</sub>R<sub>4</sub>, -NR<sub>3</sub> (CO) R<sub>4</sub>, -COOR<sub>3</sub>, -CONR<sub>3</sub>R<sub>4</sub>, -CH=CHCOOR<sub>3</sub>, -CF<sub>3</sub>, -CN, -NO<sub>2</sub>, SO<sub>3</sub>H, PO<sub>3</sub>H or halogen, wherein R<sub>3</sub> and R<sub>4</sub> represent H or lower alkyl,
- R<sub>b</sub> represents H, OH, -OSO<sub>2</sub>Me, -OSO<sub>2</sub>W wherein W represents optionally substituted aryl or heteroaryl, -OCO(CHOH)<sub>2</sub>COOR<sub>5</sub> wherein R<sub>5</sub> represents H or lower alkyl; or represents the formula -Sp<sub>3</sub>-R<sub>6</sub>,
  wherein Sp<sub>3</sub> represents a covalent bond, -O-, -OCH<sub>2</sub>-, -OSO<sub>2</sub>CH<sub>2</sub>-, -OSO<sub>2</sub>-, -OSO<sub>2</sub>(p) C<sub>6</sub>H<sub>4</sub>O- and R<sub>6</sub> represents one of carbohydrate structures A-D:

Paper Dated: April 7, 2006
In Reply to USPTO Corresponder

In Reply to USPTO Correspondence of N/A

Attorney Docket No. 0115-061069

$$R_7O_{I,I}$$
  $OR_8$   $OR_8$   $OR_8$   $OR_8$   $OR_8$   $OR_8$   $OR_8$   $OR_8$   $OR_8$   $OR_9$   $OR_{13}$   $OR_{7}$   $OR_{8}$   $OR_{15}$   $OR_{15}$   $OR_{15}$   $OR_{14}$   $OR_{11}$   $OR_{11}$   $OR_{11}$   $OR_{11}$   $OR_{11}$ 

wherein

R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub> and R<sub>14</sub> represent independently of each other H, lower alkyl, aryl(1ower alkyl), -CO-lower alkyl, -CO-aryl, -SO<sub>3</sub> or -PO<sub>3</sub>,

R<sub>10</sub> represents -CH<sub>2</sub>OR<sub>16</sub> or -COOR<sub>17</sub>, and

 $R_{15}$  represents  $-CH_2OR_{16}$ ,  $-COOR_{17}$ ,  $-CH_2NH_2$ ,  $-CH_2OPO_3$  or  $-CH_2OSO_3$ , wherein  $R_{16}$  and  $R_{17}$  independently of each other represent H, lower alkyl, aryl (lower alkyl), -CO-lower alkyl, -CO-aryl,  $-SO_3$  or  $-PO_3$ ,

- Z represents optionally substituted aryl or heteroaryl,
- Sp<sub>1</sub> represents a spacer unit, such as a straight-chain or branched lower alkyl group  $-(CH_2)_p$ -, wherein p is from 2-6, which is unsubstituted, mono or poly-substituted by -OH,  $-OR_{18}$ , halogen or cyano group, wherein one or more  $-CH_2$  groups may independently be replaced by -O-, -CO-, -CO-O-, -O-CO-,  $-NR_{19}$ -,  $-NR_{19}$ -CO-, -CO-NR<sub>19</sub>-, -CH=CH-, -C=C- and wherein R<sub>18</sub> and R<sub>19</sub> represent a hydrogen atom or lower alkyl;
- Sp<sub>2</sub> represents an optional spacer unit, such as a covalent bond or a straight-chain or branched lower alkyl group -(CH<sub>2</sub>)<sub>q</sub>-, wherein q is from 1-6, which is unsubstituted, mono or poly-substituted by -OH, -OR<sub>20</sub>, halogen or cyano group, wherein one or more -CH<sub>2</sub>- groups may independently be replaced by -O-, -CO-, -CO-O-, -O-CO-, -NR<sub>21</sub>-, -NR<sub>21</sub>-CO-, -CO-NR<sub>21</sub>-, -CH=CH-, -C≡C- -and wherein R<sub>20</sub>, and R<sub>21</sub>,

Page 3

{W0261552.1}

represents a hydrogen atom or lower alkyl;

Y represents optionally substituted aryl or heteroaryl,

with the proviso, that if P = -N <, n=1,  $X = -CO_-$  and  $Sp_2$  represents a covalent bond,  $R_6$  may not represent carbohydrate structures A or D for  $Sp_3 = -O_-$  and  $R_6$  may not represent carbohydrate B for  $Sp_3 = -OCH_2$ .

- 2. (Original): A compound according to claim 1, with the proviso, that if P = -N <, n=1, X = -CO- and  $Sp_2$  represents a covalent bond,  $R_b$  may not represent H or OH and  $Sp_3$  may not represent a covalent bond, -O- or -OCH<sub>2</sub>-.
- 3. (Currently Amended): A compound according to elaims 1 or 2claim 1, wherein P = -N <, n = 1 and X = -CO -, -CS -,  $-CH_2 -$  or -NH -.
- 4. (Currently Amended): A compound according to claims 1 or 2 claim 1, wherein P = -N <, n = 1 and X = -CS-,  $-CH_2$  or -NH-.
- 5. (Currently Amended): A compound according to claims 1 or 2claim 1, wherein P = -N <and  $-(X)_n = -OOC_{-}, -COO_{-}, -CONH_{-}, -CH=N_{-}.$
- 6. (Currently Amended): A compound according to elaims 1 or 2claim 1, wherein P = -C =and  $-(X)_n = -NH-N =$ or -O-N =.
- 7. (Currently Amended): A compound according to elaims 1 or 2claim 1, having the formula IVa

$$Y \longrightarrow SP_{1,...} \longrightarrow SP_{2}$$
 $(X)_{n} \longrightarrow P$ 
 $Z \longrightarrow R_{a}$ 
 $IVa$ 

Page 4

Application No. Not Yet Assigned Paper Dated: April 7, 2006 In Reply to USPTO Correspondence of N/A Attorney Docket No. 0115-061069

wherein Ra, Rb, Spl, Sp2, P, X, Y, Z and n are as defined in claims 1 or 2 claim 1.

8. (Currently Amended): A compound according to elaims 1 or 2claim 1 having the formula IVb,

$$R_{22}$$
 $R_{21}$ 
 $R_{21}$ 
 $R_{21}$ 

wherein  $R_a$ ,  $R_b$ ,  $Sp_l$ , P, X and n are as defined hereinabove and wherein  $R_{21}$  and  $R_{22}$  represent H, lower alkyl, lower alkoxy or halogen.

9. (Currently Amended): A compound according to elaims 7 or 8 claim 7, wherein P = -N <, n = 1 and X = -CO -, -CS -,  $-CH_2 -$  or -NH -.

10. (Currently Amended): A compound according to elaims 7 or 8 claim 7, wherein P = -N <, n = 1 and  $X = -CS_{-}$ ,  $-CH_{2}$ - or  $-NH_{-}$ .

11. (Currently Amended): A compound according to elaims 7 or 8 claim 7, wherein  $P = -N < \text{and } -(X)_{n-} = -OOC-, -COO-, -CONH-, -CH=N-.$ 

12. (Currently Amended): A compound according to claims 7 or 8 claim 7, wherein  $P = -C = \text{and } -(X)_{n^-} = -NH-N = \text{or } -O-N = .$ 

13. (Currently Amended): A pharmaceutical composition comprising a therapeutically effective amount of a compound of any preceding claim 1 with a pharmaceutically acceptable carrier.

Paper Dated: April 7, 2006

In Reply to USPTO Correspondence of N/A

Attorney Docket No. 0115-061069

14. (Original): A pharmaceutical composition according to claim 13 for the treatment or prevention of artheriosclerosis or for the reduction of cholesterol levels.

15. (Original): A kit comprising a pharmaceutical composition according to claim 13 for use in the treatment or prevention of artheriosclerosis or for the reduction of cholesterol levels.

16. (Currently Amended): A method for the treatment or prevention of artheriosclerosis or for the reduction of cholesterol levels comprising administering to a subject in need of such treatment an effective amount of a compound according to elaims 1 to 12 claim 1.

17. (Cancelled)